Changjiang Pharmaceutical Group News

Express News | Changjiang Pharmaceutical Group: The subsidiary Changjiang Star has been ruled by the court to accept the restructuring application.

BreakingsMar 14 19:45

Express News | Changjiang Pharmaceutical Group: Terminated the illegal related guarantees.

BreakingsMar 7 18:38

Shanxi Meijin Energy (000723.SZ) participates in the public recruitment of investors for the reorganization of Changjiang Pharmaceutical Group.

Shanxi Meijin Energy (000723.SZ) announced that the company and the SiChuan Capital Markets Relief and Development Securities Investment Fund Partnership...

Zhitong FinanceMar 6 19:03

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 3 10:09

Changjiang Pharmaceutical Group (300391.SZ): Subsidiary Changjiang Star has been petitioned for reorganization by creditors.

On February 12, Glorious Hong Kong announced that Changjiang Pharmaceutical Group (300391.SZ) disclosed that its subsidiary Hubei Changjiang Star Pharmaceutical Co., Ltd. (hereinafter referred to as "Changjiang Star") received the acceptance notice for the case from the Intermediate People's Court of Shiyan City, Hubei Province, numbered (2025) E 03 Bankruptcy Application No. 9. The applicant, Wuhan Century Baima System Engineering Co., Ltd., applied to the Shiyan Intermediate Court for the bankruptcy reorganization of Changjiang Star on the grounds that Changjiang Star is unable to pay its due debts and is clearly lacking in repayment ability, but still possesses reorganization value and feasibility. The Shiyan Intermediate Court filed the case on February 11, 2025.

Gelonghui FinanceFeb 12 18:59

A-share activity丨Changjiang Pharmaceutical Group hit a 20cm limit down, with an annual expected loss and negative Assets.

On January 24, Gregor Holdings (300391.SZ) once hit the lower limit of 20 cm, currently reported at 4.06 yuan, with a total market value falling below 1.5 billion yuan. According to news, the company expects a net income loss of 0.5 billion to 0.75 billion yuan for the entire year of 2024, and projects that the net assets at the end of 2024 will be negative. This year, the company is expected to recognize asset impairment losses and credit impairment losses of around 0.673 billion yuan. In addition, the company has initiated pre-restructuring, but there is uncertainty regarding whether it can enter the restructuring process. If the court decides to accept the restructuring application, the company's stock trade will be subject to delisting risk warning. (Gregor Holdings)

Gelonghui FinanceJan 24 13:35

Changyao Holdings: 2024 Annual Results Forecast

SZSIJan 24 00:00 · Announcements

Express News | Changjiang Pharmaceutical Group: The company's Stocks Trade may be subject to Delisting risk warning.

BreakingsJan 23 18:44

Express News | Changjiang Pharmaceutical Group: It is expected that the net assets at the end of 2024 will be negative. The estimated net income attributable to the shareholders of the listed company for 2024 is a loss of 0.5 billion yuan to 0.75 billion yuan, compared

BreakingsJan 23 18:35

Express News | Changjiang Pharmaceutical Group: Wholly-owned subsidiary Yihang Technology plans to borrow 20 million yuan from Zhao Chunmei.

BreakingsDec 31, 2024 20:44

Changjiang Pharmaceutical Group (300391.SZ): Its main business includes traditional Chinese medicine decoction pieces, pharmaceutical wholesale, photovoltaic equipment, etc.

Grainews, November 12th ︱ Changjiang Pharmaceutical Group (300391.SZ) stated on the investor interaction platform that the company's main business currently includes traditional chinese medicine decoctions, pharmaceutical wholesales, photovoltaic equipment, etc. In addition, the company's subsidiary Ningxia Changjiang Pharmaceutical Liangsheng has launched various tea drinks and medicinal food homologous products, including 15 liver-nourishing teas with authentic Chinese wolfberry and astragalus as the formula, 20 damp-dispelling teas, 9 Eight Treasures teas, as well as compressed confectioners and other medicinal food homologous varieties.

Gelonghui FinanceNov 12, 2024 15:51

Changyao Holdings: Report for the third quarter of 2024

SZSIOct 30, 2024 00:00 · Announcements

changjiang pharmaceutical group (300391.SZ): net loss of 0.181 billion yuan in the first three quarters.

On October 29, Gelonhui reported that Changjiang Pharmaceutical Group (300391.SZ) released its third quarter report for 2024, achieving revenue of 0.101 billion yuan in the first three quarters of the year, a year-on-year decrease of 90.12%; net income attributable to the shareholders of the listed company was -0.181 billion yuan; net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was -0.179 billion yuan; basic earnings per share was -0.5166 yuan.

Gelonghui FinanceOct 29, 2024 23:41

A-share traditional chinese medicine stocks rise, Changjiang Pharmaceutical Group's stock price rises more than 7%.

Gelonghui on October 24th | Changjiang Pharmaceutical Group rose more than 7%, Datang Pharmaceutical, Biogateway, chengdu Huasun Technology Group Inc., Ltd., teyi pharmaceutical group, *Special Treat Dadi Pharmaceutical, Guiyang Xintian Pharmaceutical and others also followed the rise.

Gelonghui FinanceOct 24, 2024 09:38

Express News | Changjiang Pharmaceutical Group: Director Li Xuan resigns due to personal reasons.

BreakingsOct 11, 2024 20:25

Changyao Holdings: 2024 Semi-Annual Report Summary

SZSIAug 30, 2024 00:00 · Announcements

Changyao Holdings: 2024 Semi-Annual Report

SZSIAug 30, 2024 00:00 · Announcements

Changjiang Pharmaceutical Group (300391.SZ) has released its first-half performance, with a net loss of 0.153 billion yuan, an increase of 530.08%.

Changjiang Pharmaceutical Group (300391.SZ) released the 2024 interim report, and the company's revenue was 7365....

Zhitong FinanceAug 29, 2024 22:56

Changjiang Pharmaceutical Group (300391.SZ): The net loss in the first half of the year was 0.153 billion yuan.

Changjiang Pharmaceutical Group (300391.SZ) announced its 2024 semi-annual report, with revenue for the reporting period of 73.6537 million yuan, a year-on-year decrease of 84.53%; net income attributable to shareholders of listed companies was -0.153 billion yuan, with a widened year-on-year loss; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was -0.15 billion yuan; basic earnings per share was -0.4355 yuan.

Gelonghui FinanceAug 29, 2024 21:01

Express News | Changjiang Pharmaceutical Group has established a health industry company which includes a planting industry of traditional Chinese herbs.

BreakingsJul 26, 2024 16:07